Published study records

Study records for Semax

Study records describe published research and its limitations. They do not establish efficacy, safety, or suitability for any use.

Study record counts

315 study records.

8 evidence-verified · 248 citation-verified · 59 citation-only

Verified records by research setting

Human research: 22
In vitro: 52
In vivo/preclinical: 182
Review/meta-analysis: 0
Other: 0

Current study records

Study type: In vivo/preclinical · Status: Evidence verified by machine against declared source

Genes That Associated with Action of ACTH-like Peptides with Neuroprotective Potential in Rat Brain Regions with Different Degrees of Ischemic Damage.

International journal of molecular sciences · 2025

Study scale: Not published. The text held for this field did not answer this heading, so nothing is shown here and nothing is substituted for it.

Abstract only: Open source record

Product or molecular entity relationships

Semax: Exact entity relationship. Legacy citation custody associates this source with the catalog record; no product-relevance conclusion is implied.

Summary withheld

No summary text is published for this record: the text held for each field did not answer the heading it was filed under. This does not change the record’s review status.

Research question

Not published. The text held for this field did not answer this heading, so nothing is shown here and nothing is substituted for it.

Study design

Not published. The text held for this field did not answer this heading, so nothing is shown here and nothing is substituted for it.

Participants or experimental system

Not published. The text held for this field did not answer this heading, so nothing is shown here and nothing is substituted for it.

Study scale

Not published. The text held for this field did not answer this heading, so nothing is shown here and nothing is substituted for it.

Intervention or exposure

Not published. The text held for this field did not answer this heading, so nothing is shown here and nothing is substituted for it.

Comparator

Not published. The text held for this field did not answer this heading, so nothing is shown here and nothing is substituted for it.

Key findings

Not published. The text held for this field did not answer this heading, so nothing is shown here and nothing is substituted for it.

Limitations and uncertainty

Not published. The text held for this field did not answer this heading, so nothing is shown here and nothing is substituted for it.

Product relevance and evidence boundary

This record is a published study, held here with its citation and review status. It is not a statement that any catalog item is effective, safe, or suitable for any use, and nothing in it is a dose or a protocol.

Evidence verified by machine against declared source. Verification is limited to the declared source and review scope. It does not mean independent replication or establish efficacy, safety, or suitability.

Study type: In vivo/preclinical · Status: Evidence verified by machine against declared source

The Potential of the Peptide Drug Semax and Its Derivative for Correcting Pathological Impairments in the Animal Model of Alzheimer's Disease.

Acta naturae · 2025

Study scale: Not published. The text held for this field did not answer this heading, so nothing is shown here and nothing is substituted for it.

Abstract only: Open source record

Product or molecular entity relationships

Semax: Exact entity relationship. Legacy citation custody associates this source with the catalog record; no product-relevance conclusion is implied.

Summary withheld

No summary text is published for this record: the text held for each field did not answer the heading it was filed under. This does not change the record’s review status.

Research question

Not published. The text held for this field did not answer this heading, so nothing is shown here and nothing is substituted for it.

Study design

Not published. The text held for this field did not answer this heading, so nothing is shown here and nothing is substituted for it.

Participants or experimental system

Not published. The text held for this field did not answer this heading, so nothing is shown here and nothing is substituted for it.

Study scale

Not published. The text held for this field did not answer this heading, so nothing is shown here and nothing is substituted for it.

Intervention or exposure

Not published. The text held for this field did not answer this heading, so nothing is shown here and nothing is substituted for it.

Comparator

Not published. The text held for this field did not answer this heading, so nothing is shown here and nothing is substituted for it.

Outcomes examined

Not published. The text held for this field did not answer this heading, so nothing is shown here and nothing is substituted for it.

Key findings

Not published. The text held for this field did not answer this heading, so nothing is shown here and nothing is substituted for it.

Limitations and uncertainty

Not published. The text held for this field did not answer this heading, so nothing is shown here and nothing is substituted for it.

Product relevance and evidence boundary

Study type: In vitro · Status: Evidence verified by machine against declared source

Semax, a Copper Chelator Peptide, Decreases the Cu(II)-Catalyzed ROS Production and Cytotoxicity of aβ by Metal Ion Stripping and Redox Silencing.

Bioinorganic chemistry and applications · 2025

Study scale: Not reported in the declared source.

Abstract only: Open source record

Product or molecular entity relationships

Semax: Exact entity relationship. Legacy citation custody associates this source with the catalog record; no product-relevance conclusion is implied.

Summary withheld

No summary text is published for this record: the text held for each field did not answer the heading it was filed under. This does not change the record’s review status.

Research question

Not published. The text held for this field did not answer this heading, so nothing is shown here and nothing is substituted for it.

Study design

Not published. The text held for this field did not answer this heading, so nothing is shown here and nothing is substituted for it.

Participants or experimental system

Not published. The text held for this field did not answer this heading, so nothing is shown here and nothing is substituted for it.

Intervention or exposure

Not published. The text held for this field did not answer this heading, so nothing is shown here and nothing is substituted for it.

Comparator

Not published. The text held for this field did not answer this heading, so nothing is shown here and nothing is substituted for it.

Outcomes examined

Not published. The text held for this field did not answer this heading, so nothing is shown here and nothing is substituted for it.

Key findings

Not published. The text held for this field did not answer this heading, so nothing is shown here and nothing is substituted for it.

Limitations and uncertainty

Not published. The text held for this field did not answer this heading, so nothing is shown here and nothing is substituted for it.

Product relevance and evidence boundary

Study type: In vivo/preclinical · Status: Evidence verified by machine against declared source

Synthetic Adrenocorticotropic Peptides Modulate the Expression Pattern of Immune Genes in Rat Brain following the Early Post-Stroke Period.

Genes · 2023

Study scale: Not published. The text held for this field did not answer this heading, so nothing is shown here and nothing is substituted for it.

Abstract only: Open source record

Product or molecular entity relationships

Semax: Exact entity relationship. Legacy citation custody associates this source with the catalog record; no product-relevance conclusion is implied.

Summary withheld

No summary text is published for this record: the text held for each field did not answer the heading it was filed under. This does not change the record’s review status.

Research question

Not published. The text held for this field did not answer this heading, so nothing is shown here and nothing is substituted for it.

Study design

Not published. The text held for this field did not answer this heading, so nothing is shown here and nothing is substituted for it.

Participants or experimental system

Not published. The text held for this field did not answer this heading, so nothing is shown here and nothing is substituted for it.

Study scale

Not published. The text held for this field did not answer this heading, so nothing is shown here and nothing is substituted for it.

Intervention or exposure

Not published. The text held for this field did not answer this heading, so nothing is shown here and nothing is substituted for it.

Comparator

Not published. The text held for this field did not answer this heading, so nothing is shown here and nothing is substituted for it.

Outcomes examined

Not published. The text held for this field did not answer this heading, so nothing is shown here and nothing is substituted for it.

Key findings

Not published. The text held for this field did not answer this heading, so nothing is shown here and nothing is substituted for it.

Limitations and uncertainty

Not published. The text held for this field did not answer this heading, so nothing is shown here and nothing is substituted for it.

Product relevance and evidence boundary

Study type: In vivo/preclinical · Status: Evidence verified by machine against declared source

Effect of ACTH4-10Pro8-Gly9-Pro10 on anti-inflammatory cytokine (IL-4, IL-10, IL-13) expression in acute spinal cord injury models (male Sprague Dawley rats).

F1000Research · 2023

Study scale: Not published. The text held for this field did not answer this heading, so nothing is shown here and nothing is substituted for it.

Abstract only: Open source record

Product or molecular entity relationships

Semax: Exact entity relationship. Legacy citation custody associates this source with the catalog record; no product-relevance conclusion is implied.

Summary withheld

No summary text is published for this record: the text held for each field did not answer the heading it was filed under. This does not change the record’s review status.

Research question

Not published. The text held for this field did not answer this heading, so nothing is shown here and nothing is substituted for it.

Study design

Not published. The text held for this field did not answer this heading, so nothing is shown here and nothing is substituted for it.

Participants or experimental system

Not published. The text held for this field did not answer this heading, so nothing is shown here and nothing is substituted for it.

Study scale

Not published. The text held for this field did not answer this heading, so nothing is shown here and nothing is substituted for it.

Intervention or exposure

Not published. The text held for this field did not answer this heading, so nothing is shown here and nothing is substituted for it.

Comparator

Not published. The text held for this field did not answer this heading, so nothing is shown here and nothing is substituted for it.

Outcomes examined

Not published. The text held for this field did not answer this heading, so nothing is shown here and nothing is substituted for it.

Key findings

Not published. The text held for this field did not answer this heading, so nothing is shown here and nothing is substituted for it.

Limitations and uncertainty

Not published. The text held for this field did not answer this heading, so nothing is shown here and nothing is substituted for it.

Product relevance and evidence boundary

Study type: In vitro · Status: Evidence verified by machine against declared source

Semax, a Synthetic Regulatory Peptide, Affects Copper-Induced Abeta Aggregation and Amyloid Formation in Artificial Membrane Models.

ACS chemical neuroscience · 2022

Study scale: Not published. The text held for this field did not answer this heading, so nothing is shown here and nothing is substituted for it.

Abstract only: Open source record

Product or molecular entity relationships

Semax: Exact entity relationship. Legacy citation custody associates this source with the catalog record; no product-relevance conclusion is implied.

Public plain-language summary

Some fields are not published, because the text held for them did not answer their heading. The published text is limited to the declared source and preserves reported uncertainty. It does not establish efficacy, safety, suitability, or evidence strength.

Research question

Not published. The text held for this field did not answer this heading, so nothing is shown here and nothing is substituted for it.

Study design

It has previously been shown that Aβ1–42 oligomeric aggregates form insoluble amyloid deposits in the brain and hippocampus and exhibit neurotoxic effects in in vitro and in vivo models, leading to the cognitive dysfunction prevalent in the pathogenesis of AD.82,83 Thus, to assess the cytotoxicity of the oligomeric species, the effect of Aβ1–42 at different preparations of oligomerization on the viability of d-SH-SY5Y cells was investigated via an MTT assay (Figure 6).

Participants or experimental system

The principal hallmark of Alzheimer’s disease is the appearance in the hippocampal region of the brain4 of proteinaceous deposits inside neuronal cells, called neurofibrillary tangles, mainly constituted by fibrillar aggregates of phosphorylated tau protein,5 and in the extracellular space, called amyloid plaques, mainly constituted by fibrillar aggregates of amyloid beta protein (Aβ).6 Amyloid β protein is the final product of the aberrant cleavage of amyloid precursor protein (APP).7

Study scale

Not published. The text held for this field did not answer this heading, so nothing is shown here and nothing is substituted for it.

Intervention or exposure

Not published. The text held for this field did not answer this heading, so nothing is shown here and nothing is substituted for it.

Comparator

Not published. The text held for this field did not answer this heading, so nothing is shown here and nothing is substituted for it.

Outcomes examined

Not published. The text held for this field did not answer this heading, so nothing is shown here and nothing is substituted for it.

Key findings

Not published. The text held for this field did not answer this heading, so nothing is shown here and nothing is substituted for it.

Limitations and uncertainty

Not published. The text held for this field did not answer this heading, so nothing is shown here and nothing is substituted for it.

Product relevance and evidence boundary

Study type: In vivo/preclinical · Status: Evidence verified by machine against declared source

Antistress Action of Melanocortin Derivatives Associated with Correction of Gene Expression Patterns in the Hippocampus of Male Rats Following Acute Stress.

International journal of molecular sciences · 2021

Study scale: Not reported in the declared source.

Abstract only: Open source record

Product or molecular entity relationships

Semax: Exact entity relationship. Legacy citation custody associates this source with the catalog record; no product-relevance conclusion is implied.

Summary withheld

No summary text is published for this record: the text held for each field did not answer the heading it was filed under. This does not change the record’s review status.

Participants or experimental system

Not published. The text held for this field did not answer this heading, so nothing is shown here and nothing is substituted for it.

Key findings

Not published. The text held for this field did not answer this heading, so nothing is shown here and nothing is substituted for it.

Product relevance and evidence boundary

Limitations and uncertainty

Not reported in the declared source.

Study type: In vivo/preclinical · Status: Evidence verified by machine against declared source

Correction of long-lasting negative effects of neonatal isolation in white rats using semax.

Acta naturae · 2012

Study scale: Not published. The text held for this field did not answer this heading, so nothing is shown here and nothing is substituted for it.

Abstract only: Open source record

Product or molecular entity relationships

Semax: Exact entity relationship. Legacy citation custody associates this source with the catalog record; no product-relevance conclusion is implied.

Summary withheld

No summary text is published for this record: the text held for each field did not answer the heading it was filed under. This does not change the record’s review status.

Research question

Not published. The text held for this field did not answer this heading, so nothing is shown here and nothing is substituted for it.

Study design

Not published. The text held for this field did not answer this heading, so nothing is shown here and nothing is substituted for it.

Participants or experimental system

Not published. The text held for this field did not answer this heading, so nothing is shown here and nothing is substituted for it.

Study scale

Not published. The text held for this field did not answer this heading, so nothing is shown here and nothing is substituted for it.

Intervention or exposure

Not published. The text held for this field did not answer this heading, so nothing is shown here and nothing is substituted for it.

Comparator

Not published. The text held for this field did not answer this heading, so nothing is shown here and nothing is substituted for it.

Outcomes examined

Not published. The text held for this field did not answer this heading, so nothing is shown here and nothing is substituted for it.

Key findings

Not published. The text held for this field did not answer this heading, so nothing is shown here and nothing is substituted for it.

Limitations and uncertainty

Not published. The text held for this field did not answer this heading, so nothing is shown here and nothing is substituted for it.

Product relevance and evidence boundary

Study type: In vivo/preclinical · Status: Citation identity verified

Intranasal Semax Attenuates Behavioral and Cognitive Deficits in a Rat Model of LPS-induced Neuroinflammation

SSRN Electronic Journal · 2026

Study scale: Not reported in the declared source.

Citation only: Open source record

Product or molecular entity relationships

Semax: Catalog source association. Legacy citation custody associates this source with the catalog record; no product-relevance conclusion is implied.

No public summary

No plain-language summary is published in this record. Summary availability is separate from its review status. Consult the cited publication when a public link is available.

Limitations and uncertainty

Not reported in the declared source.

Citation identity verified. Verification is limited to the declared source and review scope. It does not mean independent replication or establish efficacy, safety, or suitability.

Study type: Human research · Status: Citation identity verified

Modulation of neuropathological pathways by bioactive peptides and proteins/polypeptides: Targeting oxidative stress in neurodegenerative diseases.

Neuropeptides · 2025

Study scale: Not reported in the declared source.

Citation only: Open source record

Product or molecular entity relationships

Semax: Catalog source association. Legacy citation custody associates this source with the catalog record; no product-relevance conclusion is implied.

No public summary

No plain-language summary is published in this record. Summary availability is separate from its review status. Consult the cited publication when a public link is available.

Limitations and uncertainty

Not reported in the declared source.

Citation identity verified. Verification is limited to the declared source and review scope. It does not mean independent replication or establish efficacy, safety, or suitability.

Study type: In vitro · Status: Citation identity verified

The Effect of Peptide Semax, an ACTH(4-10) Analogue, on Intracellular Calcium Dynamics in Rat Brain Neurons.

Bulletin of experimental biology and medicine · 2025

Study scale: Not reported in the declared source.

Citation only: Open source record

Product or molecular entity relationships

Semax: Catalog source association. Legacy citation custody associates this source with the catalog record; no product-relevance conclusion is implied.

No public summary

No plain-language summary is published in this record. Summary availability is separate from its review status. Consult the cited publication when a public link is available.

Limitations and uncertainty

Not reported in the declared source.

Citation identity verified. Verification is limited to the declared source and review scope. It does not mean independent replication or establish efficacy, safety, or suitability.

Study type: In vivo/preclinical · Status: Citation identity verified

THE ADAPTOGENIC EFFECT OF SEMAX IN WISTAR RATS DURING SHORT-TERM PHYSICAL EXERTION

AVICENNA BULLETIN · 2025

Study scale: Not reported in the declared source.

Citation only: Open source record

Product or molecular entity relationships

Semax: Catalog source association. Legacy citation custody associates this source with the catalog record; no product-relevance conclusion is implied.

No public summary

No plain-language summary is published in this record. Summary availability is separate from its review status. Consult the cited publication when a public link is available.

Limitations and uncertainty

Not reported in the declared source.

Citation identity verified. Verification is limited to the declared source and review scope. It does not mean independent replication or establish efficacy, safety, or suitability.